---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-267965"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2022-10-25T23:59:59+00:00"
generated_at: "2026-06-23T01:22:16.957112+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology increases ownership in MICA subsidiary to 92% for $30.7M

## Summary
- Purchased 14.97M shares from Avalon Ventures and Bregua Corp at $2.05/share, totaling $30.7M.
- Ownership in MICA (holder of CLN-619 rights) increased from 54% to 92%.
- MICA holds worldwide rights to CLN-619, a monoclonal antibody targeting MICA/MICB pathway.
- Phase I trial of CLN-619 (monotherapy + combo with checkpoint inhibitor) on track for initial data in mid-2023.
- Myeloma Investment Fund (MMRF) retained its existing ownership stake in MICA.

## SEC filing metadata
- accession: 0001193125-22-267965
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2022-10-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312522267965/0001193125-22-267965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312522267965/d390289d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-267965
- JSON: https://secwatch.observer/filing/0001193125-22-267965.json
- Plain text: https://secwatch.observer/filing/0001193125-22-267965.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.